๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Follicular Lymphoma
Clinical trial register · China

Follicular Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Tianjin 6 Zhengzhou 6 Xiamen 6 Guangzhou 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Tianjin6 Zhengzhou6 Xiamen6 Guangzhou6
All 32 locations
Target enrolment
to

Follicular Lymphoma trials in China

28 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471Follicular Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
960
Beijing, Shanghai
2026-06-22
Not yet open
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
NCT07609446Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Observational
30
Suzhou
2026-05-01
Not yet open
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT07585747Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Recruiting
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2026-04-10
Recruiting
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
NCT07299149Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
34
Tianjin
2025-12-25
Not yet open
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naรฏve Advanced Stage Follicular Lymphoma
NCT07126678Follicular Lymphoma, Treatment Naive
The First Affiliated Hospital with Nanjing Medical University
Not applicable
15
Nanjing
2025-07-15
Not yet open
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
NCT07024147B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2025-07-01
Not yet open
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
NCT06918015BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy
Zhejiang Cancer Hospital
Phase 2
58
Hangzhou
2025-05-01
Recruiting
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
NCT06826118Lymphoma, Follicular Lymphoma, Refractory Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-02-08
Recruiting
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
NCT06704555Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-12-20
Not yet open
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
NCT06549335Follicular Lymphoma
Ruijin Hospital
Phase 2
66
Shanghai
2024-12-01
Active, closed
A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma
NCT06742879Follicular Lymphoma
Zhengzhou University
Observational
37
Zhengzhou
2024-05-01
Not yet open
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
NCT06368167Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
105
Beijing
2024-04
Recruiting
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
NCT06553352Follicular Lymphoma, Newly Diagnosed
The First Affiliated Hospital of Xiamen University
Phase 2
39
Xiamen
2024-03-31
Not yet open
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Observational
150
Beijing
2023-12-28
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
NCT05899621Follicular Lymphoma
Ruijin Hospital
Observational
332
Shanghai
2023-06-01
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Observational
50
Tianjin
2022-11-01
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Recruiting
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
NCT04989621Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma
Sun Yat-sen University
Phase 2
32
Guangzhou
2021-08-01
Active, closed
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/follicular-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies listing the condition Follicular Lymphoma.

How many Follicular Lymphoma trials are recruiting in China?

15 of the 28 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Follicular Lymphoma), 28 studies
PhaseStudiesRecruitingShare
Phase 213846.4%
Observational5217.9%
Phase 35217.9%
Phase 1/2217.1%
Not applicable113.6%
Phase 1103.6%
Phase 2/3113.6%

Most active sponsors

Lead sponsors with the most studies (Follicular Lymphoma)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China43
The First Affiliated Hospital of Xiamen University44
Merck Sharp & Dohme LLC21
Ruijin Hospital21
BeOne Medicines11
Celgene11
Epizyme, Inc.10
Hoffmann-La Roche10
Incyte Corporation10
Janssen Research & Development, LLC11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.